Weekly dose-dense paclitaxel and carboplatin in recurrent ovarian carcinoma: A phase II trial

Purpose: the aim of this study was to investigate efficacy and toxicity of the dose-dense weekly paclitaxel (t) and carboplatin (c) in the management of platinum-resistant/sensitive recurrent epithelial ovarian cancer (eoc) previously treated with 3 weekly paclitaxel/carboplatin. methods: thirty two patients with recurrent eoc who had received 3 weekly tc before were enrolled. nine patients relapsed within 6months (platinum-resistant),13 patients relapsed after 12months (platinum-sensitive) and in 10 patients recurrence occurred between 6 and 12months (intermediate platinum-sensitive). weekly (t) at a dose of 80mg/m2,followed by weekly (c) auc 2 on day 1,8,and 15 of a 28-day cycle for 6 planned cycles were administrated. end-points were overall response rate (orr),progression free survival (pfs),overall survival (os) and toxicity. results: the orr was 62.5%. for the platinum-resistant,intermediate platinum-sensitive and platinum-sensitive patients the orr was 44.4% (4/9),60% (6/10) and 76.9% (10/13),respectively,and 1 (11.1%),2 (20%) and 5 (38.46%) patients,respectively had cr. pfs was 9.1. months (6.13,9.1 and 12.17. months,for the 3 groups,respectively) (p<. 0.001). os was 14. months (9.17,15.2,and 19.23. months,for the 3 groups,respectively) (p<. 0.001). treatment-related adverse events were manageable with only 1 patient (3.1%) suffering from grade 4 neutropenia. grade 3 hematological and non-hematological toxicities were neutropenia in 8 (25%),and peripheral neuropathy in 4 (12.5%) patients,respectively. conclusion: weekly tc is active and well-tolerated in platinum-resistant and platinum-sensitive patients with recurrent eoc previously treated with tc given every 3 weeks. © 2014.